Furthermore, both breast cancer mutations implicated an increased tyrosine phosphorylation of the critical FGFR2 substrate FRS2 and an increased MEK1/2 and STAT3 activation in response to FGF1 stimulation leading to an accelerated cell signaling. The gene discussed is FGF1; the disease is breast cancer.